T Brendan Murphy
Overview
Explore the profile of T Brendan Murphy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
840
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McAloon C, Wall P, Butler F, Codd M, Gormley E, Walsh C, et al.
BMC Public Health
. 2021 Dec;
21(1):2238.
PMID: 34886842
Background: Contact tracing is conducted with the primary purpose of interrupting transmission from individuals who are likely to be infectious to others. Secondary analyses of data on the numbers of...
2.
Moghaddam S, Jalali A, ONeill A, Murphy L, Gorman L, Reilly A, et al.
Cancers (Basel)
. 2021 Aug;
13(16).
PMID: 34439316
This study undertook to predict biochemical recurrence (BCR) in prostate cancer patients after radical prostatectomy using serum biomarkers and clinical features. Three radical prostatectomy cohorts were used to build and...
3.
Gilgunn S, Murphy K, Stockmann H, Conroy P, Murphy T, Watson R, et al.
Int J Mol Sci
. 2020 Dec;
21(23).
PMID: 33287410
The diagnosis and treatment of prostate cancer (PCa) is a major health-care concern worldwide. This cancer can manifest itself in many distinct forms and the transition from clinically indolent PCa...
4.
Jalali A, Foley R, Maweni R, Murphy K, Lundon D, Lynch T, et al.
BMC Med Inform Decis Mak
. 2020 Jul;
20(1):148.
PMID: 32620120
Background: Prostate cancer (PCa) represents a significant healthcare problem. The critical clinical question is the need for a biopsy. Accurate risk stratification of patients before a biopsy can allow for...
5.
Scrucca L, Fop M, Murphy T, Raftery A
R J
. 2016 Nov;
8(1):289-317.
PMID: 27818791
Finite mixture models are being used increasingly to model a wide variety of random phenomena for clustering, classification and density estimation. is a powerful and popular package which allows modelling...
6.
Foley R, Maweni R, Gorman L, Murphy K, Lundon D, Durkan G, et al.
BJU Int
. 2016 Feb;
118(5):706-713.
PMID: 26833820
Objective: To analyse the performance of the Prostate Cancer Prevention Trial Risk Calculator (PCPT-RC) and two iterations of the European Randomised Study of Screening for Prostate Cancer (ERSPC) Risk Calculator,...
7.
Foley R, Gorman L, Sharifi N, Murphy K, Moore H, Tuzova A, et al.
BJU Int
. 2015 Apr;
117(3):409-17.
PMID: 25847734
Objectives: To analyse the clinical utility of a prediction model incorporating both clinical information and a novel biomarker, p2PSA, in order to inform the decision for prostate biopsy in an...
8.
Oon S, Fanning D, Fan Y, Boyce S, Murphy T, Fitzpatrick J, et al.
Prostate
. 2012 Mar;
72(14):1523-31.
PMID: 22415934
Background: Accurate preoperative staging of prostate cancer (PCa) is important but current diagnostic methods cannot accurately determine extracapsular extension (ECE), resulting in the possible triage of patients towards a less...
9.
Rowan F, Docherty N, Murphy M, Murphy T, Coffey J, OConnell P
Ann Surg
. 2010 Nov;
252(5):869-75.
PMID: 21037444
Objective: To optimize total bacterial 16S rRNA quantification in microdissected colonic crypts in healthy controls and patients with ulcerative colitis (UC) and to characterize the findings with disease activity. Background:...
10.
Fan Y, Murphy T, Watson R
Bioinformatics
. 2009 Aug;
25(22):3033-4.
PMID: 19706743
Unlabelled: 2D Difference In-Gel Electrophoresis (2D-DIGE) or 2D gel technology is being used as a routine proteomics technique for biomarker discovery. Analyzing such high-dimensional data requires multivariate analysis techniques to...